Roche Spent 1b For The Leading Molecular Information Biotechо Swiss pharma giant roche just announced paying $1b to acquire 56% percent of leading molecular information and genomic analysis. The swiss company, which went public on its local exchange last year, saw its share price fall about 6% on the news. while roche is out the door, molecular partners recently deepened its.
Roche Spent 1b For The Leading Molecular Information Biotechо In 2013 the roche group employed over 85,000 people worldwide, invested 8.7 billion swiss francs in r&d and posted sales of 46.8 billion swiss francs. genentech, in the united states, is a wholly owned member of the roche group. roche is the majority shareholder in chugai pharmaceutical, japan. for more information, please visit roche . About roche. throughout our 125 year history, roche has grown into one of the world’s largest biotech companies, as well as a leading provider of in vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas. our commitment to our people, partners, stakeholders and, most importantly, our patients. All 10 of the roche group‘s top 10 selling pharmaceuticals are blockbusters that have sales of more than 1b chf per year. the roche group also currently has one of the strongest pharmaceutical development pipelines in the industry, with biotechnology products accounting for a significant part of all projects. Around 66% of the total us$26 billion vc investment in biotech in 2021 went to early stage deals, compared with a 15 year average of around 59%. over the past five years, early stage vc investment has totaled us$69.3 billion — nearly doubling the us$34.9 billion the industry raised over the previous 10 years.
Comments are closed.